Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537416 | 0.83 | CYP2D6 (0.52) | CYP2C9CYP2D6ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL12833903 | 0.81 | CDK4 (0.47) | CYP2C9CYP2D6ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2815473 | 0.81 | ALDH1A1 (0.50) | CYP2C9CYP2D6ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5754456 | 0.79 | CYP2D6 (0.53) | CYP2C9CYP2D6SYKALDH1A1KDM4E | |
| SCHEMBL12833435 | 0.78 | CDK4 (0.47) | CYP2C9CYP2D6MEN1KMT2AHPGD | |
| SCHEMBL5653271 | 0.77 | CYP2D6 (0.61) | CYP2C9CYP2D6ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13145231 | 0.76 | CYP2C9 (0.51) | CYP2C9CYP2D6ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL12834188 | 0.76 | CDK4 (0.52) | CYP2C9CYP2D6ALDH1A1KDM4EMAPT | |
| SCHEMBL537370 | 0.76 | ALOX15 (0.51) | ALDH1A1HPGD | |
| SCHEMBL5957538 | 0.75 | KDM4E (0.53) | CYP2C9CYP2D6ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410144-B2 | Substituted indolo-pyridinone compounds | ARQULE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2414344-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114896-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114896-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249127-A1 | SUBSTITUTED INDOLO-PYRIDINONE COMPOUNDS | MKI67, CCNI, CDK4 | CYP2C9 1143/4885CYP2D6 359/4885SYK 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.